

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業(開曼)控股有限公司

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6998)**

### VOLUNTARY ANNOUNCEMENT THE INCLUSION OF LEROCICLIB (GB491) IN CHINA'S NATIONAL REIMBURSEMENT DRUG LIST

The announcement is made by Genor Biopharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) announces that Lerociclib (GB491) has been included in the 2025 edition of the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (“**National Reimbursement Drug List**”) published by the National Healthcare Security Administration of China on 7 December 2025. This is the first time that Lerociclib (GB491) has been included in the National Reimbursement Drug List. The new edition of the National Reimbursement Drug List will take effect from 1 January 2026.

Lerociclib (GB491) is a novel, highly potent, selective, oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i), which is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with:

- an aromatase inhibitor as initial endocrine-based therapy;
- fulvestrant in patients with disease progression following endocrine therapy.

The Company believes that the inclusion of Lerociclib (GB491) in the NRDL will not only significantly enhance patients' access to medication and reduce their financial burden, but also accelerate the commercialization and market penetration of Lerociclib (GB491) and further increase the returns for innovation.

By Order of the Board  
**Genor Biopharma Holdings Limited**  
**Mr. Weng Chengyi**  
*Executive Director and Chief Financial Officer*

Hong Kong, 8 December 2025

*As at the date of this announcement, the Board comprises six (6) Directors, namely Mr. Weng Chengyi (Chief Financial Officer) as an executive Director; Mr. Yu Tieming and Mr. Liu Yi as non-executive Directors; and Ms. Cui Bai, Mr. Fung Edwin and Mr. Chen Wen as independent non-executive Directors.*